Introduction
Polymer-lipid hybrid nanoparticles (PLN) are an emerging nanoparticle drug delivery system made of polymers and lipids taking advantages of both materials. PLN are solid at body temperature, which is similar to solid lipid nanoparticles (SLN), [1, 2] but different from the traditionally referred lipidbased nanoparticles -liposomes that consist of an aqueous core enclosed in a lipid bilayer. The coexistence of polymer and lipid possessing different material properties, such as hydrophobicity and water-solubility, imparts PLN versatile capability of loading varying types of payloads, which is different from SLN and nanostructured lipid carriers that are mainly for loading hydrophobic compounds. Compared to other types of nanoparticle drug carriers, PLN exhibit a number of unique advantages including (1) wide selections of biocompatible polymers and lipids and numerous polymer-lipid combinations, (2) easy fabrication by a single-step method, and (3) superior capability of co-encapsulating therapeutic and imaging agents of different properties. PLN formulations have been demonstrated to increase drug loading efficiency, enable controlled drug release, improve drug uptake and intracellular drug transport, and circumvent membrane efflux transportermediated multidrug resistance (MDR) in cancer cells. Like other types of nanocarriers, PLN can also be conjugated with targeting moieties for targeted drug delivery to tumor vasculature and tumor cells. Because of these advantages, PLN system is of tremendous potential for delivery of a broad range of therapeutic agents. However, it is challenging to design optimal formulations with all desirable characteristics for specific applications such as cancer chemotherapy. This editorial article provides an overview of PLN formulations with a focus on injectables for cancer therapy, representative examples, and discusses the key factors, strategies, and future in the development of PLN for effective delivery of individual or combinatorial therapeutic agents.
Emergence and progress of PLN development
PLN were initially devised in late 1990s and early 2000 to mitigate the problem of loading water-soluble, ionic drugs in hydrophobic solid lipid phase to achieve adequate loading and sustained release of such drugs. [1, 3] Since then, various PLN formulations have been developed to encapsulate a single anticancer drug, [4] or co-encapsulate a drug with a chemosensitizer, [1, 3] a drug with a P-glycoprotein (P-gp) inhibitor, [5] or dual anticancer drugs of synergy. [6] PLN formulations have also been developed to deliver biologics for gene therapy and immunotherapy, including siRNA [7] or siRNA with an anticancer drug. [8] PLN formulations have been shown to circumvent efflux transporter-mediated multidrug resistance (MDR) in cancer cells [1, 4, 6, 9] and increase antitumor efficacy while reducing systemic toxicity of the anticancer drugs. [10, 11] It was found that the PLN facilitated drug uptake and retention in P-gp overexpressing cancer cells, provided effective intracellular drug release, transported the drug (e.g. doxorubicin) to the nuclei where drug target (i.e. DNA) is located, [4, 6, 10] and enabled spatiotemporal co-delivery and local bioavailability of anticancer drugs in solid tumor and cancer cells. [12] Owing to these unique properties and more desired drug release kinetics than clinically used liposomal doxorubicin (Doxil®/Caelyx®) which has a long release half-life of 118 hours, a PLN formulation with co-encapsulated synergistic anticancer drugs, that is, doxorubicin and mitomycine C, outperformed Doxil®/Caelyx® in MDR cancer cells and in preclinical tumor models. [10] [11] [12] 
Composition and design of PLN
Biocompatible polymers have been used to make PLN including poly(lactic-co-glycolic acid) (PLGA), dextran sulfate, polyethylenimine (PEI), and a polymer derived from soy bean oil. Lipids in PLN formulations are those already used in pharmaceutical products, such as phospholipids, polyethylene glycol (PEG)-lipid, extracts of food products (e.g. lecithin), or found in the body (e.g. endogenous fatty acids). Up to date, reported PLN formulations can be divided into two major categories as schematically illustrated in Figure 1 : type A -monolithic matrix PLN, where polymer and drug(s) are homogeneously distributed in the solid lipid matrix, [1, [3] [4] [5] [6] [9] [10] [11] [12] and type Bcore-shell PLN, where drug-containing polymer core is covered by a single layer of phospholipid. [7, 8, 13] The latter is sometimes called lipid-polymer hybrid nanoparticles (LPN) in literature. [7, 8, 13] Figure 1(a) and (b) portray the representative components and procedures used for preparation of type A PLN formulation for cationic drug (a) or anionic siRNA (b). For loading a cationic drug, for example, doxorubicin HCl or verapamil HCl, an anionic polymer, such as dextran sulfate or hydrolyzed polymer of epoxidized soybean oil was employed to neutralize the charge of the drug and bring the drug to melted lipid phase. After ultrasonication of the polymer-drug complex with the melted lipid in the presence of surfactants, for example, Tween 80 and Pluronic F68, or lipid-PEG, the emulsion was then cooled in a cold aqueous medium forming solid PLN. Type A PLN can be prepared in one-pot with a little or no organic solvent. The second drug or both drugs can be nonionic and hydrophobic (e.g. Elacridar). Drug loading content and loading efficiency can be maximized and drug release kinetics can be tailored by rational selection of type of lipid and polymer and lipid to polymer ratio. [13, 14, 15] The drug to lipid ratio and cosurfactant concentration and ratio were optimized to obtain desirable loading efficiency and particle size. [15] In cases of loading hydrophobic drug(s) only, a hydrophobic polymer, for example, PLGA, can be used with lipid to form PLN, which is more straightforward as the polymer and lipid would be quite miscible. By utilizing cationic polymers, for example, chitosan and PEI, anionic drugs and biologics, such as DNA and siRNA can be encapsulated in PLN. The wide selections of polymers, lipids, and their combinations render type A PLN tremendous versatility for single delivery or codelivery of a variety of payloads ranging from small molecules to macromolecules and from water-soluble drugs to poorly water-soluble drugs. Moreover, type A PLN can be made 'stealth' for prolonged systemic circulation by introducing PEG-lipid of two different chain lengths. [6, [9] [10] [11] [12] The core-shell (type B) PLN utilize the advantage of hydrophobic polymer core for sustained drug release and lipid (bi) layer to mimic hydrophilic liposomal surface. PEG chains can also be conjugated on the surface to achieve long circulation of the nanoparticles. Type B PLN are normally prepared by a two-step method (Figure 1(c) top) . The drug-loaded polymer core is synthesized by oil-in-water emulsion and solvent evaporation, where a hydrophobic polymer, for example, PLGA is dissolved in an organic solvent together with the drug. The prepared drug-loaded polymer core is then mixed with rehydrated, preformed lipid film or liposomes to form lipid bilayer or multilayer-coated polymer nanoparticles. A new one-step nanoprecipitation method was developed to make lipid monolayer-coated polymer-drug core PLN (Figure 1(c) bottom). [13] In this experiment, ester-terminated PLGA and drug were dissolved in acetonitrile, while lecithin and phospholipidconjugated PEG in heated ethanol and water. The PLGA-drug solution was dropwise added to the surfactant solution, vortexed, stirred and formed type B PLN by self-assembly. [13] Figure 1 (d) portrays another example of type B PLN where siRNA was loaded at the interface between polymer core and cationic lipid in the shell by ionic complexation. [7] 
Expert opinion
The ultimate goal of research in PLN-mediated drug delivery is to develop effective and safe therapy for clinic use. Development of PLN formulations with increased efficacy and reduced toxic side effects is particularly important for improving cancer therapy where toxicity is always associated with therapeutic efficacy. Over the past 15 years, the field of PLN-mediated drug delivery has been developed quickly to achieve this goal. All reported PLN formulations are made by simple preparation methods from polymers, lipids, and surfactants that have been used in approved pharmaceutical products, or are generally regarded as safe (GRAS). This mentality in the field is healthy and crucial for translating preclinical results to nanomedicines that can benefit millions of people suffered from cancer and other diseases. Use of pharmaceutical and GRAS excipients would accelerate product development by removing one hurdle to regulatory approval of the products. Therefore, it is expected to see PLN formulations being moved to clinical trials in the next few years.
Combining different properties of diverse polymers and lipids in PLN presents a tremendous opportunity for development of PLN to suit various drug delivery needs, especially for combination therapies via co-delivery of multiple agents of distinct properties. The research in the field has already demonstrated the unique advantages and great potential of PLN platform, which will warrant further development of PLN formulations for clinic use. Successful design of PLN formulations requires comprehensive consideration of basic properties of nanoparticle drug carriers, that is, drug loading capacity, loading efficiency, particle size, surface charge, colloidal stability, and spatiotemporal drug release. These properties can be optimized by rational selection of polymer, lipid, surfactant, and their relative ratios by theoretical calculations, physicochemical characterization, and optimization tools. [14, 15] Physicochemical compatibility and affinity are essential for efficiently loading the drug into PLN and precisely controlling drug release kinetics. Hence, thorough understanding of material properties in relation to physicochemical properties of PLN is beneficial for successful design of PLN.
For delivering anticancer agents to solid tumors via systemic injection, spatiotemporal drug release from PLN is critical as it directly impacts the efficacy and toxicity of the treatment. However, current techniques for measuring drug release kinetics of nanoparticles are inaccurate for in vitro test and virtually impossible for in vivo test. Conventional pharmacokinetic measurement of drug concentration in plasma and organs could not correlate well with therapeutic efficacy, typified by liposomal doxorubicin (Doxil®/Caelyx®), as it fails to distinct released drug from unreleased drug. Because only the released drug, instead of total amount of drug in the tumor, is bioavailable for generating therapeutic effects, [12] it is important to seek advanced technologies for evaluating in vivo drug release, local bioavailability, and therapeutic response.
An exciting and interesting application of PLN is delivery of synergistic drug combinations. The multiple components in PLN impart them capability of loading multiple agents in one carrier and releasing the payloads at different times and intracellular locations. Good knowledge about how biological systems process polymers, lipids, and surfactants, and about mechanisms of drug action could help optimal design of PLN. For example, by tailoring the structure and material of PLN, siRNA can be released in cytoplasm rapidly while a codelivered anticancer drug being released in nuclei slower. [7, 8] 
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